SEC filing · 10-K

Aytu Biopharma, Inc: Annual report

Aytu BioPharma launched EXXUA in fiscal 2026 while shifting commercial focus away from declining legacy product lines.

Filed September 22, 2026 · period ended June 30, 2026

Mixed for the company

What the numbers say

Revenue fell 13% to $57.6M versus the prior year; operating margin narrowed from -11.8% to -14.4%; diluted EPS -$1.16 versus -$2.16; operating cash flow $3.3M (a year earlier -$1.9M); free cash flow $3.3M (a year earlier -$2.2M); cash fell by $4.6M to $26.3M while debt fell by $1.8M; diluted share count up 96% (dilution).

Compared with the same period a year earlier, from the figures Aytu Biopharma, Inc reported to the SEC.

What happened

Aytu recorded total net revenue of $57.6 million and a net loss of $14.3 million for the fiscal year ended June 30, 2026.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Aytu Biopharma, Inc

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.